WallachBeth analyst Bob Ai raised his price target for Clovis Oncology (CLVS) to $134 and recommends buying the stock both as a fundamental story and potential takeover target. The updated data from AstraZeneca (AZN) at the World Conference on Lung Cancer suggest that AZD9291 and Clovis' Rociletinib have similar efficacy, Ai tells investors in a research note titled "Better Competitive Position Adding to its Appeal in the Eyes of Potential Suitors." Clovis shares should go up more despite yesterday's 13.8% rally now that Rociletinib looks as good as AZD9291, the analyst argues. Ai believes Clovis is now more attractive to potential suitors. The company focused on anti-cancer agents closed yesterday up $11.67 to $96.05.

Unusual total active option classes on open include: Wrap Technologies (WRAP), AstraZeneca (AZN), JetBlue (JBLU), United Continental (UAL), Taiwan Semi (TSM), Nokia (NOK), EBay (EBAY), Maplebear Inc (CART), Airbnb (ABNB), and UnitedHealth (UNH).